ATE492562T1 - Rekombinanter antikörper gegen humanen insulin- like growth factor - Google Patents

Rekombinanter antikörper gegen humanen insulin- like growth factor

Info

Publication number
ATE492562T1
ATE492562T1 AT04773541T AT04773541T ATE492562T1 AT E492562 T1 ATE492562 T1 AT E492562T1 AT 04773541 T AT04773541 T AT 04773541T AT 04773541 T AT04773541 T AT 04773541T AT E492562 T1 ATE492562 T1 AT E492562T1
Authority
AT
Austria
Prior art keywords
antibody
growth factor
human insulin
antibody fragment
recombinant antibody
Prior art date
Application number
AT04773541T
Other languages
English (en)
Inventor
Kenya Shitara
Kazuyasu Nakamura
Yuji Ohki
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE492562T1 publication Critical patent/ATE492562T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04773541T 2003-09-24 2004-09-24 Rekombinanter antikörper gegen humanen insulin- like growth factor ATE492562T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003331509 2003-09-24
PCT/JP2004/014453 WO2005028515A1 (ja) 2003-09-24 2004-09-24 ヒトインスリン様成長因子に対する遺伝子組換え抗体

Publications (1)

Publication Number Publication Date
ATE492562T1 true ATE492562T1 (de) 2011-01-15

Family

ID=34373044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04773541T ATE492562T1 (de) 2003-09-24 2004-09-24 Rekombinanter antikörper gegen humanen insulin- like growth factor

Country Status (7)

Country Link
US (1) US7498415B2 (de)
EP (1) EP1676862B1 (de)
JP (1) JP4620591B2 (de)
AT (1) ATE492562T1 (de)
CA (1) CA2540138C (de)
DE (1) DE602004030700D1 (de)
WO (1) WO2005028515A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8195659B2 (en) * 2005-08-23 2012-06-05 Ricoh Co. Ltd. Integration and use of mixed media documents
EP1979001B1 (de) 2005-12-13 2012-04-11 Medimmune Limited Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CA2723722A1 (en) * 2008-05-09 2009-11-12 Dyax Corp. Igf-ii/gf-iie binding proteins
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
HUE026374T2 (en) 2008-12-12 2016-05-30 Boehringer Ingelheim Int Anti-IGF antibody
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CA2774953A1 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CA2896082A1 (en) * 2012-12-21 2014-06-26 Joel R. L. Ehrenkranz Supplements and monitoring systems for dosing of the supplements
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SG11202010025YA (en) 2018-05-31 2020-11-27 Glyconex Inc Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
CA3105222A1 (en) 2018-07-17 2020-01-23 Humabs Biomed Sa Antibodies against campylobacter species
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
DK3872091T3 (da) 2020-02-26 2023-09-11 Vir Biotechnology Inc Antistoffer mod sars-cov-2
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
BR112022020706A2 (pt) 2020-04-14 2022-11-29 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
AU2021268361A1 (en) 2020-05-08 2022-12-08 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
AU2021288203A1 (en) 2020-06-12 2023-01-19 Vir Biotechnology, Inc. Antibody therapies for SARS-CoV-2 infection
EP4217385A2 (de) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antikörper gegen sars-cov-2
TW202235105A (zh) 2020-11-23 2022-09-16 美商維爾生物科技股份有限公司 抗流感抗體及其組合
CA3197537A1 (en) 2020-11-23 2022-05-27 Davide Corti Antibodies against influenza a viruses
US20240092876A1 (en) 2020-11-23 2024-03-21 Vir Biotechnology, Inc. Broadly neutralizing antibodies against influenza neuraminidase
TW202235107A (zh) 2020-11-25 2022-09-16 美商維爾生物科技股份有限公司 結合至多種乙型冠狀病毒的抗體
US20220259319A1 (en) * 2021-01-21 2022-08-18 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
AU2022280767A1 (en) 2021-05-24 2024-01-18 Humabs Biomed Sa Engineered polypeptides
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
WO2023034866A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2023230445A2 (en) 2022-05-23 2023-11-30 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2024026411A1 (en) 2022-07-27 2024-02-01 Humabs Biomed Sa Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (de) 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
AU1232188A (en) * 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
OA12589A (en) * 2001-01-05 2006-06-08 Abgenix Inc Antibodies to insulin-like growth factor i receptor.
ATE444972T1 (de) 2002-04-30 2009-10-15 Kyowa Hakko Kirin Co Ltd ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR
JP2003310275A (ja) * 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
WO2005018671A1 (ja) * 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤

Also Published As

Publication number Publication date
CA2540138C (en) 2013-07-30
EP1676862A1 (de) 2006-07-05
EP1676862A4 (de) 2007-08-08
JP4620591B2 (ja) 2011-01-26
CA2540138A1 (en) 2005-03-31
JPWO2005028515A1 (ja) 2007-11-15
EP1676862B1 (de) 2010-12-22
WO2005028515A1 (ja) 2005-03-31
US7498415B2 (en) 2009-03-03
US20060240015A1 (en) 2006-10-26
DE602004030700D1 (de) 2011-02-03

Similar Documents

Publication Publication Date Title
ATE492562T1 (de) Rekombinanter antikörper gegen humanen insulin- like growth factor
Ponnapakkam et al. Treating osteoporosis by targeting parathyroid hormone to bone
ES2310192T3 (es) Uso de peptidos glp-2.
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
EP3300721A1 (de) Propylenglykolhaltige peptidformulierungen, die zur herstellung und zum einsatz in einspritzvorrichtungen optimal sind
AR082767A1 (es) Terapia para la diabetes
MY158627A (en) Halogen-stabilized insulin
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
MX2009003569A (es) Metodo de administracion de farmacos para la proteina anabolica osea.
TW200630327A (en) Substituted phenylalkanoic acids
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200630354A (en) Substituted amino carboxylic acids
WO2007120557A3 (en) Method and apparatus of low strengh electric field network-mediated delivery
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
WO2003079991A3 (en) Method for administration of growth hormone via pulmonary delivery
WO2002096195A8 (en) Treatment or replacement therapy using transgenic stem cells delivered to the gut
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
JP2014129405A5 (de)
WO2007109648A3 (en) Compositions and methods for modulating store-operated calcium entry
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
TW200631949A (en) Substituted carboxylic acids
TW200628168A (en) Use of organic compounds
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
GB2559761A (en) Composition for improved bone fracture healing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties